Annualized Bleeding Rate (ABR) ‐ All treated bleeds · people without inhibitors
1 finding from 1 review
Annualized joint Bleeding Rate (AjBR) · people without inhibitors
1 finding from 1 review
Annualized spontaneous Bleeding Rate (AsBR) · people without inhibitors
1 finding from 1 review
Proportion with zero bleeds · people without inhibitors
Summary of findings table ‐ Fitusiran prophylaxis probably leads to higher proportion with zero bleeds compared with on‐demand therapy (moderate certainty).
1 finding from 1 review
QoL · people without inhibitors
1 finding from 1 review
All adverse events · people without inhibitors
Summary of findings table ‐ Fitusiran prophylaxis probably leads to higher all adverse events compared with on‐demand therapy (moderate certainty).
1 finding from 1 review
Adverse events ‐ Serious adverse events · people without inhibitors
Summary of findings table ‐ Fitusiran prophylaxis showed no clear difference in adverse events ‐ Serious adverse events compared with on‐demand therapy (moderate certainty).
1 finding from 1 review
QoL · people with inhibitors
1 finding from 1 review
All adverse events · people with inhibitors
Summary of findings table ‐ Emicizumab prophylaxis probably leads to higher all adverse events compared with on‐demand therapy (moderate certainty).
1 finding from 1 review
Serious adverse events · people with inhibitors
Summary of findings table ‐ Emicizumab prophylaxis showed no clear difference in serious adverse events compared with on‐demand therapy (moderate certainty).
1 finding from 1 review
Annualized Bleeding Rate (ABR) ‐ All treated bleeds · people with inhibitors
1 finding from 1 review
Annualized spontaneous Bleeding Rate (AsBR) · people with inhibitors
1 finding from 1 review
Cases of cholera ( · healthy children and adults; high risk population
1 finding from 1 review
Cases of cholera ( · healthy children and adults; high risk population
3 findings from 1 review
no estimate extracted
1 study · 54519 participants
High
no estimate extracted
2 studies · 168540 participants
Moderate
no estimate extracted
2 studies · 241631 participants
High
Cases of cholera ( · healthy children and adults, male and female; high risk population
2 findings from 1 review
Cases of severe dehydrating cholera ( · healthy children and adults, male and female; high risk population
2 findings from 1 review
Apixaban (all doses combined) vs placebo · adults after AMI without an indication for anticoagulation
3 findings from 1 review
no estimate extracted
2 studies · 8638 participants
Moderate
no estimate extracted
2 studies · 8638 participants
Moderate
no estimate extracted
2 studies · 8544 participants
High
Rivaroxaban (all doses combined) vs placebo · adults after AMI without an indication for anticoagulation
3 findings from 1 review
no estimate extracted
3 studies · 21870 participants
High
no estimate extracted
3 studies · 21870 participants
Moderate
no estimate extracted
3 studies · 21870 participants
High
Dabigatran (all doses combined) vs placebo · adults after AMI without an indication for anticoagulation
3 findings from 1 review
no estimate extracted
1 study · 1861 participants
Low
no estimate extracted
1 study · 1861 participants
Low
no estimate extracted
1 study · 1861 participants
Low
Reduction in pain intensity · Morton's neuroma
1 finding from 1 review